
Good Therapeutics sells PD-1 IL-2 program to Roche for $250M and will march on with a similar name, but in Latin
There’s Just, and there’s Good.
The first was sold in summer 2019. And the PD-1 IL-2 portion of the latter is now entering the fold of Roche.
The two biotechs aren’t related, but Good Therapeutics founder and CEO John Mulligan “liked the idea of having Good and Just in Seattle,” calling his startup’s moniker a “riff” on the Evotec-acquired Just Biotherapeutics.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.